Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients
Financing will enable Stargazer to advance development of STG-001 through a pivotal clinical study in Stargardt Disease BOSTON (PRWEB) NOVEMBER 09, 2020 Stargazer Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel treatment options for rare eye diseases, announced it has completed a Series A financing totalling $57 million from leading investors Novo Holdings, […]
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
— ORR of 64% Observed in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer — ORR of 75% and One Complete Response Observed in Patients with 1L Head and Neck Cancer — ALX Oncology to Host Conference Call on November 16 at 5:00pm EST BURLINGAME, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint […]
